Welcome to our dedicated page for BANK BRADESCO SEC filings (Ticker: BBD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BANK BRADESCO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BANK BRADESCO's regulatory disclosures and financial reporting.
Banco Bradesco S.A. reports that all items on the agenda of its combined Annual and Special Shareholders’ Meetings held in March 2026 were approved. These approvals cover a capital increase, amendments to the bank’s bylaws and the election or reelection of board and fiscal council members.
Most board members, including Luiz Carlos Trabuco Cappi and several others, were reelected, while some new members joined both the Board of Directors and the Fiscal Council through a single slate proposed by controlling shareholders. All approved changes will only take effect after authorization by the Central Bank of Brazil.
Banco Bradesco S.A. as a foreign private issuer filed an amended Form 6-K outlining its 2026 corporate calendar. The bank plans to release quarterly information for 2026 on May 6, July 29, and October 28.
The filing also schedules the 2026 annual shareholders’ meeting, with the management proposal and call notice sent on February 6 and the meeting held on March 10. A videoconference with analysts to present third-quarter 2026 results is set for October 29. The document includes a standard cautionary note on forward-looking statements.
Banco Bradesco S.A. released consolidated remote voting results for its Annual and Special Shareholders’ Meetings scheduled for March 10, 2026. Shareholders largely backed a R$6.67 billion capitalization of the “Profit Reserves - Legal Reserve” to raise stock capital from R$87.1 billion to R$93.77 billion without issuing new shares.
They also supported bylaw changes to permit profit sharing for management and reflect the higher capital. At the annual meeting, shareholders approved the 2025 financial statements, allocation of 2025 net income, election of an 11‑member Board of Directors and the Fiscal Council, and compensation for 2026, including R$873,048,000.00 for overall management remuneration, R$36,952,000.00 for the pension plan, and specific annual fees for Fiscal Council members.
Banco Bradesco gave an update on its plan to consolidate its healthcare businesses into Odontoprev S.A. through a merger of shares and related asset contribution. Management of Bradesco Gestão de Saúde, Odontoprev, Bradesco and Bradseg signed a First Amendment to the merger protocol to include appraisal-report information used to determine Odontoprev’s capital increase, without changing the deal’s terms and conditions.
Following this, an Extraordinary General Shareholders’ Meeting of Odontoprev was convened to approve the merger of BGS into Odontoprev, the resulting capital increase, amendments to Odontoprev’s bylaws including a new corporate name, “Bradsaúde S.A.”, and the asset contribution to Mediservice Operadora de Planos de Saúde S.A.
Banco Bradesco S.A. provides its 2026 corporate and reporting calendar. The bank plans to release quarterly information for 2026 on 05/05/2026 (1st quarter), 07/29/2026 (2nd quarter) and 10/28/2026 (3rd quarter).
The annual shareholders’ meeting materials, including the management proposal and call notice, are scheduled to be sent on 02/06/2026, with the meeting set for 03/10/2026. A videoconference with analysts to discuss 3rd-quarter 2026 results is planned for 10/29/2026. The text also reiterates standard cautionary language about forward-looking statements and related risks and uncertainties.
Banco Bradesco S.A. is calling an extraordinary general meeting for March 31, 2026 to approve the partial spin-off of its wholly owned subsidiary Bradseg Participações S.A., with spun-off net assets of R$ 16,136,310,439.65 being absorbed by Bradesco. The spun-off portion consists of all shares of Bradesco Gestão de Saúde S.A. and Bradseg’s stake in Odontoprev S.A., as the first step in a broader transaction to consolidate Bradesco’s healthcare businesses under Odontoprev. The spin-off will not increase Bradesco’s capital or issue new shares, so there is no shareholder dilution or withdrawal right. Management highlights expected administrative efficiency and a more integrated health and dental offering, with estimated implementation costs around R$ 300,000.00.
Banco Bradesco S.A. called an Extraordinary General Meeting for March 31, 2026 at 4:00 p.m., to be held exclusively in digital format. Shareholders will vote on approving the partial spin-off of Bradseg Participações S.A., with the spun-off net assets absorbed by Bradesco.
This spin-off is part of a broader business combination involving Bradesco Gestão de Saúde S.A. and Odontoprev S.A., with the goal of unifying Bradesco’s health-segment equity interests in Odontoprev. After all stages are completed, Odontoprev is expected to consolidate Bradesco’s healthcare ecosystem, simplifying the corporate structure and potentially improving administrative efficiency.
Banco Bradesco S.A. is restructuring its healthcare businesses by consolidating them under Odontoprev S.A., which will be renamed Bradsaúde S.A.. Bradseg will be partially spun off so that Bradesco directly holds shares of Odontoprev and Bradesco Gestão de Saúde (BGS), and Odontoprev will merge the shares of BGS, making BGS its wholly owned subsidiary. Bradesco will receive 2,378,374,445 new Odontoprev shares in exchange for all BGS shares, based on an exchange ratio of 0.17998067486 Odontoprev share per BGS share. After the transaction, Bradesco will own 91.35% of Odontoprev’s total and voting capital and current Odontoprev shareholders will hold 8.65%, excluding treasury shares and any withdrawal effects. Odontoprev’s dental operations and related assets will be contributed to Mediservice, and Odontoprev/Bradsaúde will act solely as a holding company for Bradesco’s healthcare businesses. The companies highlight expected commercial synergies, broader healthcare scope, and potential Basel ratio benefits for Bradesco, while noting that the spin-off itself does not change Bradesco’s share capital and does not create withdrawal rights for Bradesco or Bradseg shareholders.